Researchers identify novel metabolic programs driving aggressive brain tumors

Researchers at Moffitt Cancer Center have identified metabolic signatures that may pave the way for personalized therapy in glioma, a type of tumor that starts in the brain.

The study appears online in the October issue of , a publication of the American Association for Cancer Research.

According to the authors, little has been known about the underlying metabolic alterations that may drive the growth of the most aggressive type of glioma, termed glioblastoma.

"For the first time, we have described global metabolomic signatures in glioma," said study corresponding author Prakash Chinnaiyan, M.D., an assistant member in Moffitt's Experimental Therapeutics Program. "This use of , which is the global quantitative assessment of metabolites within a , has enabled us to identify some of the central that allow for these tumors to grow. Our findings provide a unique insight into the underlying biology of glioma and appear to have prognostic significance."

The metabolic studies were carried out at Metabolon Inc. of Durham, N.C., using a nontargeted platform that enabled quantitative analysis of a broad spectrum of molecules.

The established approach for both understanding and treating cancer has largely been genotype based. Unfortunately, clinical gains offered by this level of understanding have been limited, largely based on the complex nature of signaling pathways associated with tumor growth and the inability to delineate the key functional signaling pathways driving growth in an individual tumor.

Chinnaiyan added that although cancers have access to a variety of such pathways, there are a limited number of metabolic strategies they can employ.

"Simply put, with regards to , there are several means to the same end. Rather than studying and targeting the means, represents the end consequence of these aberrant signaling pathways," Chinnaiyan said.

More study will be required to determine the relative importance of these and other metabolic pathways in subtype designation and their overall influence on malignant glioma metabolism. The research team wrote "understanding the glioma metabolome offers the potential for several levels of clinical application, including the possibilities for prognostication and opportunities for personalizing treatment to an individual tumor's metabolic phenotype."

Related Stories

To combat deadly brain cancer, target the stem cells

Jul 07, 2011

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found ...

New insights for a therapeutic approach in glioblastoma

Mar 18, 2011

(PhysOrg.com) -- Scientists from the Friedrich Miescher Institute for Biomedical Research have identified a new and important molecular player in glioblastoma. The amount of the MNK1 kinase is not only dramatically ...

Brain tumor vaccine has promising results

Nov 22, 2006

U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.

Recommended for you

Generation of tanners see spike in deadly melanoma

11 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

11 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

23 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments